UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2024
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Emma Walmsley |
| b) | Position/status | Chief Executive Officer |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.1277 | 8 (partnership shares) | |
| | £16.1277 | 8 (matching shares) | |
| | | | |
| d) | Aggregated information | |
Aggregated volume Price | 16 Ordinary Shares £16.1277 |
| e) | Date of the transaction | 2024-04-10 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Julie Brown |
| b) | Position/status | Chief Financial Officer |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.1277 | 7 (partnership shares) | |
| | £16.1277 | 7 (matching shares) | |
| | | | |
| d) | Aggregated information | |
Aggregated volume Price | 14 Ordinary Shares £16.1277 |
| e) | Date of the transaction | 2024-04-10 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | James Ford |
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc
|
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.1277 | 7 (partnership shares) | |
| | £16.1277 | 7 (matching shares) | |
| | | | |
| d) | Aggregated information | |
Aggregated volume Price | 14 Ordinary Shares £16.1277 |
| e) | Date of the transaction | 2024-04-10 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Sally Jackson |
| b) | Position/status | SVP, Global Communications and CEO Office |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.1277 | 8 (partnership shares) | |
| | £16.1277 | 8 (matching shares) | |
| | | | |
| d) | Aggregated information | |
Aggregated volume Price | 16 Ordinary Shares £16.1277 |
| e) | Date of the transaction | 2024-04-10 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | David Redfern |
| b) | Position/status | President Corporate Development |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.1277 | 7 (partnership shares) | |
| | £16.1277 | 7 (matching shares) | |
| | | | |
| d) | Aggregated information | |
Aggregated volume Price | 14 Ordinary Shares £16.1277 |
| e) | Date of the transaction | 2024-04-10 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Regis Simard |
| b) | Position/status | President, Global Supply Chain |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.1277 | 8 (partnership shares) | |
| | £16.1277 | 8 (matching shares) | |
| | | | |
| d) | Aggregated information | |
Aggregated volume Price | 16 Ordinary Shares £16.1277 |
| e) | Date of the transaction | 2024-04-10 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Philip Thomson |
| b) | Position/status | President, Global Affairs |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc
|
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.1277 | 8 (partnership shares) | |
| | £16.1277 | 8 (matching shares) | |
| | | | |
| d) | Aggregated information | |
Aggregated volume Price | 16 Ordinary Shares £16.1277 |
| e) | Date of the transaction | 2024-04-10 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Deborah Waterhouse |
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.1277 | 8 (partnership shares) | |
| | £16.1277 | 8 (matching shares) | |
| | | | |
| d) | Aggregated information | |
Aggregated volume Price | 16 Ordinary Shares £16.1277 |
| e) | Date of the transaction | 2024-04-10 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Victoria Whyte |
| b) | Position/status | Company Secretary |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.1277 | 8 (partnership shares) | |
| | £16.1277 | 8 (matching shares) | |
| | | | |
| d) | Aggregated information | |
Aggregated volume Price | 16 Ordinary Shares £16.1277 |
| e) | Date of the transaction | 2024-04-10 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Emma Walmsley |
| b) | Position/status | Chief Executive Officer |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.3094 | 24 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Diana Conrad |
| b) | Position/status | Chief People Officer |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.3094 | 4 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | James Ford |
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.3094 | 7 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Sally Jackson |
| b) | Position/status | SVP, Global Communications and CEO Office |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.3094 | 58 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Luke Miels |
| b) | Position/status | Chief Commercial Officer |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.3094 | 3 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | David Redfern |
| b) | Position/status | President Corporate Development |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.3094 | 69 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Regis Simard |
| b) | Position/status | President, Global Supply Chain |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.3094 | 25 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Philip Thomson |
| b) | Position/status | President, Global Affairs |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.3094 | 43 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Deborah Waterhouse |
| b) | Position/status | CEO, ViiV Healthcare |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.3094 | 56 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Victoria Whyte |
| b) | Position/status | Company Secretary |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on shares held through the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.3094 | 53 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Dylan Jackson |
| b) | Position/status | PCA of Ms S Jackson (SVP, Global Communications and CEO Office) |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024. |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.2891 | 24 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume
Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Victoria Whyte |
| b) | Position/status | Company Secretary |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.2891 | 16 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Iain Whyte |
| b) | Position/status | PCA of Ms V Whyte (Company Secretary) |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024. |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.2891 | 1090 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | David Redfern |
| b) | Position/status | Chief Strategy Officer |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024, on Ordinary Shares held within an ISA |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £15.3860 | 19 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-12 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Victoria Whyte |
| b) | Position/status | Company Secretary |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024, on Ordinary Shares held within an ISA |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £16.3860 | 16 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-12 |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Elizabeth McKee Anderson |
| b) | Position/status | Independent Non-Executive Director |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $40.9550 | 11 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-12 |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Charles Bancroft |
| b) | Position/status | Independent Non-Executive Director |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $40.9550 | 68 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-12 |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Dr Hal Barron |
| b) | Position/status | Non-Executive Director |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $40.9550 | 13 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-12 |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Dr Anne Beal |
| b) | Position/status | Independent Non-Executive Director |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $40.9550 | 9 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-12 |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Dr Harry Dietz |
| b) | Position/status | Independent Non-Executive Director |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044
|
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $40.9550 | 9 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-12 |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Dr Jesse Goodman |
| b) | Position/status | Independent Non-Executive Director |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $40.9550 | 9 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-12 |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Dr Vishal Sikka |
| b) | Position/status | Independent Non-Executive Director |
| c) | Initial notification/ amendment
| Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $40.9550 | 43 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-04-12 |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| | GSK plc |
| | (Registrant) |
| | |
| Date: April 15, 2024 | |
| | |
| | By:/s/ VICTORIA WHYTE -------------------------- |
| | |
| | Victoria Whyte |
| | Authorised Signatory for and on |
| | behalf of GSK plc |
